UC Irvine GMP facility launched in 2024 and was rebranded to Manufacturing Advanced Therapeutics and Research Innovation eXchange (MATRIX) in 2026 to better reflect our core values of scientific and operational rigor, seamless collaboration, and a relentless commitment to innovation.

UC Irvine MATRIX, a state-of-the-art cGMP facility, serves as a premier translational hub for academic researchers and biotechnology sponsors to accelerate advanced therapeutics from pre-clinical process design through early-phase clinical manufacturing for cell and gene therapies. Built to bridge the critical "bench-to-bedside" gap, the UC Irvine MATRIX facility delivers fully compliant, clinical-grade bioproduction platforms engineered to rapidly translate breakthrough discoveries into scalable therapies for early phase I-II clinical trials. Through early-stage collaboration with sponsors, we specialize in de-risking timelines through robust process and analytical development, ensuring a seamless path to clinical application.